Presentation is loading. Please wait.

Presentation is loading. Please wait.

Graphical Approaches for Safety Signal Detection Efforts of the FDA-Industry-Academia Working Group Mat Soukup, Ph.D. Acting Team Lead Biometrics 7, CDER.

Published byEllen Newton Modified over 8 years ago

Similar presentations

Presentation on theme: "Graphical Approaches for Safety Signal Detection Efforts of the FDA-Industry-Academia Working Group Mat Soukup, Ph.D. Acting Team Lead Biometrics 7, CDER."— Presentation transcript:

1 Graphical Approaches for Safety Signal Detection Efforts of the FDA-Industry-Academia Working Group Mat Soukup, Ph.D. Acting Team Lead Biometrics 7, CDER September 21, 2010

2 Disclaimer The views expressed in this presentation are those of the presenter and must not be taken to represent policy or guidance on behalf of the U.S. Food and Drug Administration

3  Reason for Working Group Formation; proof by example  Barriers to Visualizations  Developing Standard Views of Safety Data  Public Dissemination of Information  Concluding Remarks Outline

4 Example 1: Understanding the Trend Tabular Summary of SBP Over Time: Active DrugControl Drug VisitNMeanSD95% CINMeanSD95% CI 1112118.11.3(115.9, 120.3)113119.11.2(117.0, 121.2) 2112122.71.4(120.4, 125.0)112119.11.1(117.0, 121.2) 3111125.61.0(123.6, 127.6)110114.41.2(112.3, 116.5) 4110133.11.2(131.0, 135.2)108124.21.4(121.9, 126.5) 5110136.71.2(134.6, 138.8)108123.81.2(121.7, 125.9) 6108134.21.1(132.1, 136.3)108114.91.1(112.8, 117.0) 7106131.01.2(128.9, 133.1)104120.11.2(118.0, 122.2) 8105126.21.3(124.0, 128.4)103121.61.2(119.5, 123.7) 9104124.31.2(122.2, 126.4)100118.61.1(116.5, 120.7) 10102125.11.2(123.0, 127.2)100117.71.3(115.5, 119.9)

5 Example 1: Understanding the Trend Graphical Summary:

6 Example 2: Beyond Dichotomy Tabular Summary of Dichotomized Laboratory Value: CohortLow DoseHigh Dose 6 mo. – 2 yrs1/20 (5%)2/20 (10%) 2 yrs – 6 yrs0/20 (0%) 6 yrs – 12 yrs0/20 (0%) 12 yrs – 18 yrs0/20 (0%)1/20 (5%) Background : Lab Parameter Assessed at baseline and end of exposure Measured in 4 age cohorts Dichotomized at a value ≤ 18

7 Example 2: Beyond Dichotomy Graphical Summary:

8  Reason for Working Group Formation; proof by example  Barriers to Visualizations  Developing Standard Views of Safety Data  Public Dissemination of Information  Concluding Remarks Outline

9 Barriers to Graph Creation 1. Lack of Training : Statistical coursework typically does not include classes/training on graphic construction › Even more so, on good graphical principles 2. Limited Publications : Publications of graphical approaches for clinical trial data are few and far between 3. Time restraints › May require creation after data base lock 4. Software dependency › Software needed may be outside that allowed in closed computing environment

10 Remove the Barriers – Key for Future

11  Reason for Working Group Formation; proof by example  Barriers to Visualizations  Developing Standard Views of Safety Data  Public Dissemination of Information  Concluding Remarks Outline

12 FDA/Industry/Academia Working Group  Background › Formed: Fall 2009 › Membership  Regulatory (21 members)  Industry (13 members): Shering-Plough, Pfizer, GSK, Johnson and Johnson, Novartis, Eli Lilly, Merck, Sanofi-Aventis, Roche, Amgen  Academia (2 members): Vanderbilt, UC-Davis Goal: To develop a palette of graphics for visualizations of clinical trial safety data

13 Project Objectives 1. Identify areas particularly applicable or useful to regulatory review in which graphics can enhance understanding of safety information. 2. Develop a palette of statistical graphics for reporting on clinical trials safety data. 3. Recommend graphics for clinical data based on good scientific principles and best practices. 4. Create a publicly-available repository of sample graphics (ensuring appropriate credits are given for contributions), including data sets and code. 5. Educate and engage stakeholders through outreach activities. 6. Consider publishing with authorship/acknowledgments as is consistent with contributions and policy of the affiliated institution.

14 Project Scope  Includes › Graphics to convey pre-approval clinical safety information typically submitted in support of an ISS › Static graphics represented in: color, black and white, and grayscale › Graphs for both descriptive and inferential purposes › Static graphics should be printable › Develop tools that will aid in the product of new graphics  Excludes › Spontaneous reporting or epidemiological case control studies › Dynamic graphics

15 Working Group Structure Invited membership and time/resources are based on a volunteer basis Four Subgroups  ECG/Vitals (10 members)  General Adverse Events (11 members)  General Principles (9 members)  Labs/Liver (7 members)

16 Addressing the Barriers  Lack of Training : Efforts are being developed to help untrained on how to select the right graph; outreach through presentations  Limited Publications : Materials will be presented in a public forum (more to follow)  Time Restraints : Standard set of views reduces time to develop graphical approaches, can be planned upfront  Software Dependency : Code to create graphics will be publicly available; ability to use multiple software packages

17  Reason for Working Group Formation; proof by example  Barriers to Visualizations  Developing Standard Views of Safety Data  Public Dissemination of Information  Concluding Remarks Outline

18 Distribution of Content  Information will be publicly available at http://ctspedia.org http://ctspedia.org  Currently, materials require administrative authorization as: › Group is working on devising site structure › Content for safety is just being populated › Infrastructure for registration of graphics is being developed; desire for ease of entry  All content is intended to be publicly available in the near term

19 CTSpedia Screenshot Draft

20 CTSpedia Graphics Homepage Screenshot Draft

21 Describing Graphic Entries  Metadata included in the graphic library › Required Fields : Title, Description, Background, Image, Author, Dates, Use/Suitability, Software, Code, Keywords › Optional Fields : References, Data Description › Categorizations : Evaluation (e.g. safety, efficacy), Graph Type (e.g. scatterplot, dotplot), Variable Relationship (e.g. categorical vs. categorical), Data Type (e.g. continuous)

22 Graphic Example, 1 Draft

23 Graphic Example, 2 Draft

24  Reason for Working Group Formation; proof by example  Barriers to Visualizations  Developing Standard Views of Safety Data  Public Dissemination of Information  Concluding Remarks Outline

25 Reasons to Include Graphic Summaries  Complex statistical concepts and data structures can be conveyed at a level which is within reach to those with little statistical training  Ability to highlight key safety signals from large data bases  Paradigm is to actively assess the data in a manner that is visual, intuitive, and geometric

26 Potential Results Using Effective Graphics  Clinical trial results are more transparent (hard to hide the data if it is all shown)  Increases the likelihood of detecting key safety signals  Improves the ability to make clinical decisions  Allows for more productive interactions with the FDA  Improves communication to the public

27 A Community for Graphics  Several advantages exist for using a public community › Increases the talent pool for developing new approaches › Provides access to the latest information › Access to code lessens resources to implement the approach › Evolution towards a best practice in reporting safety information

28 Special Thanks The following members of the FDA/Industry/Academia Working Group  Regulatory: George Rochester, Bruce Weaver, Stephine Keeton, Janelle Charles, Chuck Cooper, Suzanne Demko, Robert Fiorentino, Richard Forshee, Eric Frimpong, Ted Guo,Pravin Jadjav, Leslie Kenna, Joyce Korvick, Antonio Paredes, Jeff Summers, Mark Walderhaug, Yaning Wang, Markus Yap, Hao Zhu  Industry: Ken Koury, Rich Anziano, Susan Duke, Mac Gordon, Fabrice Bancken, Navdeep Boparai, Andreas Bruckner, Brenda Crowe, Sylvia Engelen, Larry Gould, Matthew Gribbin, Liping Huang, Qi Jiang  Academia: Frank Harrell, Mary Banach

Download ppt "Graphical Approaches for Safety Signal Detection Efforts of the FDA-Industry-Academia Working Group Mat Soukup, Ph.D. Acting Team Lead Biometrics 7, CDER."

Similar presentations

Project Quality Plans Gillian Sandilands Director of Quality

Project Quality Plans Gillian Sandilands Director of Quality
1 of 18 Information Dissemination New Digital Opportunities IMARK Investing in Information for Development Information Dissemination New Digital Opportunities.

1 of 18 Information Dissemination New Digital Opportunities IMARK Investing in Information for Development Information Dissemination New Digital Opportunities.
Brian A. Harris-Kojetin, Ph.D. Statistical and Science Policy

Brian A. Harris-Kojetin, Ph.D. Statistical and Science Policy
The Forest for the Trees Visualizing Adverse Events Andreas Brueckner Bayer Healthcare.

The Forest for the Trees Visualizing Adverse Events Andreas Brueckner Bayer Healthcare.
Industry/FDA/Academia Safety Graphics Working Group Introduction and Overview FDA/QSPI Biostatistics, Statistical Programming, and Data Management Summit.

Industry/FDA/Academia Safety Graphics Working Group Introduction and Overview FDA/QSPI Biostatistics, Statistical Programming, and Data Management Summit.
December 14, 1999 1 FDA Advisory Committee for Pharmaceutical Science Nonclinical Studies Subcommittee Efficient advancement to clinical trials Jack A.

December 14, FDA Advisory Committee for Pharmaceutical Science Nonclinical Studies Subcommittee Efficient advancement to clinical trials Jack A.
Lessons Learned in Initiating and Conducting Risk Assessments within a Risk Analysis Framework: A FDA/CFSAN Approach Robert Buchanan DHHS Food and Drug.

Lessons Learned in Initiating and Conducting Risk Assessments within a Risk Analysis Framework: A FDA/CFSAN Approach Robert Buchanan DHHS Food and Drug.
1 MANUFACTURING AND PRODUCTION OF BIOLOGICAL PRODUCTS (ERT 455) HAZARD ANALYSIS AND CRITICAL CONTROL POINT (HACCP) SYSTEM Munira Mohamed Nazari School.

1 MANUFACTURING AND PRODUCTION OF BIOLOGICAL PRODUCTS (ERT 455) HAZARD ANALYSIS AND CRITICAL CONTROL POINT (HACCP) SYSTEM Munira Mohamed Nazari School.
Qi Jiang and Liping Huang on Behalf of the Adverse Event Sub Team

Qi Jiang and Liping Huang on Behalf of the Adverse Event Sub Team
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
STRUCTURE AND PROCESS OF PERIODIC SAFETY UPDATE REPORTING SYSTEM MEDICINES IN KENYA KIOGORA MWITI GATIMBU REG NO.U51/64042/2013 M.PHARM-EPIVIGIL 24 TH.

STRUCTURE AND PROCESS OF PERIODIC SAFETY UPDATE REPORTING SYSTEM MEDICINES IN KENYA KIOGORA MWITI GATIMBU REG NO.U51/64042/2013 M.PHARM-EPIVIGIL 24 TH.
Evaluating Physical Activity Intervention Programs Thomas Schmid, PhD Physical Activity and Health Branch CDC Atlanta, Georgia, USA.

Evaluating Physical Activity Intervention Programs Thomas Schmid, PhD Physical Activity and Health Branch CDC Atlanta, Georgia, USA.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.

FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
Codex Guidelines for the Application of HACCP

Codex Guidelines for the Application of HACCP
Why Publish? Public Health Translation Research Eric Tai, MD MS Comprehensive Cancer Control Branch Division of Cancer Prevention and Control Centers for.

Why Publish? Public Health Translation Research Eric Tai, MD MS Comprehensive Cancer Control Branch Division of Cancer Prevention and Control Centers for.
DRAFT Richard Chandler-Mant – R Consultant The Challenges of Validating R Managing R in a Commercial Environment.

DRAFT Richard Chandler-Mant – R Consultant The Challenges of Validating R Managing R in a Commercial Environment.
JumpStart the Regulatory Review: Applying the Right Tools at the Right Time to the Right Audience Lilliam Rosario, Ph.D. Director Office of Computational.

JumpStart the Regulatory Review: Applying the Right Tools at the Right Time to the Right Audience Lilliam Rosario, Ph.D. Director Office of Computational.
Preparing for and Disseminating Study Results. Overview This session will cover how to: Develop and implement a dissemination plan Correctly time the.

Preparing for and Disseminating Study Results. Overview This session will cover how to: Develop and implement a dissemination plan Correctly time the.
IAEA International Atomic Energy Agency. IAEA Outline Learning Objectives The Mission Report Purpose and objectives What is not needed? Evolution of the.

IAEA International Atomic Energy Agency. IAEA Outline Learning Objectives The Mission Report Purpose and objectives What is not needed? Evolution of the.
1 Guidelines For The Future Sharing Best Practice For National Bibliographies In The Digital Era Neil Wilson Information Coordinator IFLA Bibliography.

1 Guidelines For The Future Sharing Best Practice For National Bibliographies In The Digital Era Neil Wilson Information Coordinator IFLA Bibliography.

Similar presentations

Ads by Google